Physician

Nathan Randall Peterson, D.O.

According to 2025 Medicare claims, Nathan Peterson, D.O. (NPI: 1053459867) practices dermatology in the Lake Havasu City-Kingman, AZ market, with the plurality of this provider's patient population coming from Mohave, AZ. This provider's primary affiliated billing organization is ARIZONA DESERT DERMATOLOGY AND SURGERY PC (NPI: 1386702546; TIN: 860797917) and primary practice location at 86409-0927.

Peterson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,281 traditional Medicare patients, billed 9,956 HCPCS/CPT codes, and received $603,688 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,426 prescription claims across 564 beneficiaries totaling $782,422 in drug costs, led by Skyrizi Pen (Risankizumab-Rzaa). Open Payments data shows 9 records totaling $218. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $38,787 to $782,422. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$456K$911K2016 Medicare payment: $5,372 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $865,962 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $911,047 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $825,000 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $616,376 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $721,955 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $647,351 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $586,705 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $603,688 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
20162575$5,372
20171,78516,280$865,962
20181,87516,618$911,047
20191,79815,022$825,000
20201,48313,270$616,376
20211,33812,902$721,955
20221,28211,349$647,351
20231,25610,491$586,705
20241,2819,956$603,688

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$440K$880K2015 Drug cost: $38,787 (USD; Tot_Drug_Cst)2016 Drug cost: $193,256 (USD; Tot_Drug_Cst)2017 Drug cost: $309,631 (USD; Tot_Drug_Cst)2018 Drug cost: $435,686 (USD; Tot_Drug_Cst)2019 Drug cost: $574,985 (USD; Tot_Drug_Cst)2020 Drug cost: $749,597 (USD; Tot_Drug_Cst)2021 Drug cost: $590,099 (USD; Tot_Drug_Cst)2022 Drug cost: $582,497 (USD; Tot_Drug_Cst)2023 Drug cost: $880,018 (USD; Tot_Drug_Cst)2024 Drug cost: $782,422 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015281527$38,787
20165161,175$193,256
20174401,052$309,631
20184311,093$435,686
20194481,117$574,985
20204361,149$749,597
20214351,038$590,099
20224611,072$582,497
20235421,280$880,018
20245641,426$782,422

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths485681$81
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more1,0322,288$62
11102Biopsy of related skin growth, first growth237278$59
17000Destruction of precancer skin growth, 1 growth523834$40
17003Destruction of precancer skin growth, 2-14 growths4102,337$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Skyrizi PenRisankizumab-Rzaa171,316$374,760
Humira(Cf) PenAdalimumab24672$241,571
OtezlaApremilast13570$89,323
Clobetasol PropionateClobetasol Propionate1123,148$3,934
Doxycycline HyclateDoxycycline Hyclate31813$3,869

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.9$218ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Nathan Randall Peterson, D.O.?

Tedicare shows public-source Medicare data for Nathan Randall Peterson, D.O. (NPI 1053459867), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nathan Randall Peterson, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Nathan Randall Peterson, D.O.?

Nathan Randall Peterson, D.O. is linked to ARIZONA DESERT DERMATOLOGY AND SURGERY PC (billing NPI 1386702546) in the available physician profile data.

Does Nathan Randall Peterson, D.O. have Open Payments data?

Nathan Randall Peterson, D.O. has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.